Premium
Mebhydrolin napadisylate A possible cause of reversible agranulocytosis and neutropenia
Author(s) -
McEwen John,
Strickland William J.
Publication year - 1982
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1982.tb132554.x
Subject(s) - neutropenia , antihistamine , medicine , drug reaction , drug , adverse drug reaction , adverse effect , intensive care medicine , dermatology , pediatrics , pharmacology , toxicity
Mebhydrolin napadisylate is an antihistamine marketed in Australia as Fabahistin, and as an ingredient of Fabahistin Plus. Since June, 1973, 11 Australian reports associating this drug with either agranulocytosis or neutropenia have been received by the Adverse Drug Reactions Advisory Committee. In seven of these reports, mebhydrolin napadisylate was the only suspected drug. These reactions are probably uncommon, but the association should be borne in mind if evidence of agranulocytosis or neutropenia is found in patients taking the drug.